PubMed Health⌕ Search

Biomedical subjects

Kristl Vonck

Publications and source records attributed to Kristl Vonck.

24 records · Page 2Linked to original sources
PubMed2002

Ictal source localization in presurgical patients with refractory epilepsy.

Source localization of epileptic foci using ictal spatiotemporal dipole modeling (ISDM) yields reliable anatomic information in presurgical candidates. It requires substantial resources from EEG and neuroimaging laboratories. The profile and number of patients who may benefit from it are currently unknown. The purpose of this study is to demonstrate the clinical usefulness of source localization in a prospectively analyzed series. One hundred patients (51 male and 49 female patients) with mean age of 31 years (range, 2 to 63 years) and mean duration of refractory epilepsy of 20 years (range, 1 to 49 years) were enrolled consecutively in a presurgical protocol. Ictal EEG was available in 93 patients. ISDM was performed when suitable ictal EEG files were available. The clinical applicability of ISDM was examined in three patients groups: 37 patients in whom ictal EEG recording and MRI were congruent (group I), 30 patients in whom results were not completely congruent but not incongruent (group II), and 26 patients in whom the results were incongruent (group III). ISDM could be performed in 31 of 100 patients: 11 in group I, 8 in group II, and 12 in group III. ISDM influenced decision making in none of the patients in group I, in 4 of 8 patients in group II, and in 10 of 12 patients in group III. Typically, the results of ISDM directed avoiding intracranial EEG recordings in what appeared to be unsuitable candidates for resection by clearly confirming the incongruency between ictal EEG and MRI findings. In this series of 100 presurgical candidates, ictal source localization could be performed in 31% of patients. In 14% of patients, it proved to be a key element in the surgical decision process.

Adolescent↗
PubMed2002

Perfusion SPECT changes after acute and chronic vagus nerve stimulation in relation to prestimulus condition and long-term clinical efficacy.

UNLABELLED: Left-sided vagus nerve stimulation (VNS) is an efficacious treatment for patients with refractory epilepsy. Previous studies have implicated thalamic and mesial temporal involvement in acute stimulation. In this study, acute and chronic effects of VNS in patients with refractory complex partial seizures with or without secondary generalization (CPS +/- SG) were evaluated with respect to the prestimulus condition and long-term follow-up. METHODS: Twenty-three patients (12 females, 11 males; mean age, 32.4 +/- 10.6 y; mean CPS +/- SG duration, 21.0 +/- 11.7 y) were prospectively included. All patients were considered unsuitable candidates for resective surgery because of nonlocalizing findings in the presurgical evaluation. All underwent a split-dose (99m)Tc-ethyl cysteinate dimer activation study before and immediately after their initial stimulation (0.25 or 0.5 mA, 30 Hz) on a high-resolution triple-head gamma camera. Ten patients also underwent a SPECT activation study 5.7 +/- 1.6 mo after implantation with an additional 0.25-mA stimulus superposed on a therapeutic intensity of 1.5 +/- 0.3 mA. Data were analyzed by an automated semiquantitative volume-of-interest analysis after stereotactic anatomic standardization. RESULTS: In the acute, initial setting, the left thalamus, right parahippocampal gyrus, and right hippocampus were deactivated by VNS (P < 0.011). Acute stimulation in the chronic state resulted in a significant left thalamic activation (P < 0.001). When chronic perfusion was compared with the initial pre-VNS baseline, perfusion decreases were found in both thalami (-5.3% on the left and -3.4% on the right, P < or = 0.04). Perfusion changes in chronic VNS correlated negatively with the prestimulus perfusion pattern, indicating the tendency toward decreased brain activity on VNS. Initial stimulation changes in the right amygdala in the group of 10 patients with chronic assessment were predictive of therapeutic response (P = 0.018); in addition, right chronic hippocampal perfusion changes correlated strongly with the long-term clinical efficacy of VNS (P = 0.004). CONCLUSION: Under initial and chronic conditions, acute VNS stimulation produces different perfusion changes that are related to the interictal perfusion pattern before stimulation. The long-term mechanism of clinically effective VNS may rely on mainly hippocampal/amygdala and thalamic inhibition. Acute amygdala and chronic hippocampal perfusion changes are predictive of long-term therapeutic response in specific patient subgroups.

Adult↗
PubMed2002

Vagus nerve stimulation for refractory epilepsy.

Vagus nerve stimulation (VNS) is a neurophysiological treatment for patients with medically or surgically refractory epilepsy. Since the first human implant in 1989, more than 10,000 patients have been treated with VNS. Two randomized controlled studies have shown a statistically significant decrease in seizure frequency during a 12-week treatment period versus a baseline period when 'high stimulation' mode was compared with 'low stimulation' mode. The efficacy appears to increase over time. In general, one third of the patients show a > 50% reduction of seizure frequency; one third show a 30-50% seizure reduction, and one third of patients show no response. Few patients become seizure-free. Side effects during stimulation are mainly voice alteration, coughing, throat paraesthesia and discomfort. When studied on a long-term basis, VNS is an efficacious, safe and cost-effective treatment not only in adults but also in children and the elderly. The precise mechanism of action remains to be elucidated. In recent years much progress has been made through neurophysiological, neuroanatomical, neurochemical and cerebral blood flow studies in animals and patients treated with VNS. Further elucidation of the mechanism of action of VNS may increase its clinical efficacy and our general understanding of some physiopathological aspects of epilepsy. Finally, VNS may become an alternative treatment for other conditions such as depression and pain.

Clinical Trials as Topic↗
PubMedDate not supplied

Acute vagus nerve stimulation does not suppress spike and wave discharges in genetic absence epilepsy rats from Strasbourg.

We evaluated the efficacy of vagus nerve stimulation (VNS) in Genetic Absence Epilepsy Rats from Strasbourg (GAERS), a validated model for absence epilepsy. In the first experiment, we investigated whether VNS applied at seizure onset can interrupt spike and wave discharges (SWD). In the second experiment, we investigated whether SWD are suppressed or shortened in duration when VNS is applied several hours per day. Both control and VNS groups underwent EEG and VNS electrode implantation. For the first experiment, a randomized crossover design was used. Stimuli (amplitude: 3 V; frequency: 30 Hz; pulse duration: 500 micros) were given when an SWD occurred on the EEG. The experiment was repeated the next day. In the second experiment, treated animals were stimulated (amplitude: 1.5 mA; frequency: 30 Hz; pulse duration: 500 micros; on/off time cycle: 30 s / 5 min) for 3h per day, during five consecutive days. In the first experiment, the duration of the SWD was increased on day 1, (P < 0.05). There was no difference in SWD duration on Day 2. In the second experiment, no significant differences could be found in number, duration and EEG frequency of SWD. VNS applied at the onset of an SWD can prolong the duration of SWD in GAERS. As a 5-day stimulation protocol had no effect, long-term VNS might be necessary to affect SWD.

Action Potentials↗
PubMedDate not supplied

Vagus nerve stimulation for refractory epilepsy: a transatlantic experience.

Vagus nerve stimulation (VNS) is an alternative treatment for medically or surgically refractory epilepsy. The long-term efficacy and safety of VNS were evaluated in a large patient series at Ghent University Hospital and Dartmouth-Hitchcock Medical Center. Between March 1995 and February 2003, seizure frequency and type as well as prescribed antiepileptic drugs and side effects were prospectively assessed in 131 patients treated with VNS in either center. Patients with a minimum follow-up duration of 6 months were included in the efficacy and safety analysis. A total of 118 of 131 implanted patients had a minimum postimplantation follow-up period of 6 months (mean, 33 months). The mean age of these patients was 32 years and the mean duration of refractory epilepsy was 22 years. The mean reduction in monthly seizure frequency in all patients was 55% (range, 0-100; SD = 31.6). Seven percent of patients were free of seizures with impaired consciousness, 50% of patients had a seizure frequency reduction of more than 50%, and 21% of patients were nonresponders. Fifteen patients reported stimulation-related side effects such as hoarseness or gagging. In a large patient series from two geographically distinct epilepsy centers located in two different continents, VNS proved to be efficacious and safe during long-term follow-up.

Adolescent↗